Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OAT | P04181 | 1/20 | 1.00 |
| ▸ | ABAT | P80404 | 2/20 | 0.66 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22440735 | 0.98 | OAT (0.97) | OATABATGABRR1 | |
| SCHEMBL22459920 | 0.86 | OAT (0.76) | OATABATGABRR1 | |
| SCHEMBL22459885 | 0.86 | OAT (0.76) | OATABATGABRR1 | |
| SCHEMBL22460134 | 0.81 | OAT (0.69) | OATABATGABRR1 | |
| SCHEMBL22459893 | 0.81 | OAT (0.69) | OATABATGABRR1 | |
| SCHEMBL22459897 | 0.80 | OAT (0.67) | OATABATGABRR1 | |
| Cpp-115 Free Base SCHEMBL2407298 | 0.79 | ABAT (1.00) | OATABATGABRR1 | |
| Cpp-115 Free Base SCHEMBL21404893 | 0.79 | ABAT (1.00) | OATABATGABRR1 | |
| Cpp-115 Free Base SCHEMBL2408171 | 0.79 | ABAT (1.00) | OATABATGABRR1 | |
| Cpp-115 Free Base SCHEMBL12258069 | 0.79 | ABAT (1.00) | OATABATGABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021062048-A2 | METHODS AND SYSTEMS FOR MODULATING HEPATIC GABA PRODUCTION OR RELEASE TO ALTER FOOD INTAKE IN MONOGASTRIC SPECIES | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2021-04-01 | — | — | WO | claimed |
| US-20230128194-A1 | METHODS AND COMPOSITIONS TO ALTER HEPATIC GABA RELEASE TO TREAT OBESITY-RELATED CONDITIONS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2023-04-27 | — | — | US | disclosed |
| US-11207283-B2 | Inactivators of toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria | NORTHWESTERN UNIVERSITY (US) | 2021-12-28 | — | — | US | disclosed |
| US-11203596-B2 | Analogs of 3-amino-4-(propan-2-ylidene)cyclopentane-1-carboxylic acid and uses thereof for treating diseases and disorders associated with ornithine aminotransferase activity | NORTHWESTERN UNIVERSITY (US) | 2021-12-21 | — | — | US | disclosed |
| WO-2021203033-A2 | METHODS AND COMPOSITIONS TO ALTER HEPATIC GABA RELEASE TO TREAT OBESITY-RELATED CONDITIONS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2021-10-07 | — | — | WO | disclosed |
| EP-3215144-B1 | ORNITHINE AMINOTRANSFERASE INHIBITION WITH GABA ANALOGUES FOR TREATMENT OF HEPATOCELLULAR CARCINOMA | UNIV NORTHWESTERN (US) | 2021-04-28 | — | — | EP | disclosed |
| WO-2021062048-A2 | METHODS AND SYSTEMS FOR MODULATING HEPATIC GABA PRODUCTION OR RELEASE TO ALTER FOOD INTAKE IN MONOGASTRIC SPECIES | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2021-04-01 | — | — | WO | disclosed |
| US-20200299296-A1 | ANALOGS OF 3-AMINO-4-(PROPAN-2-YLIDENE)CYCLOPENTANE-1-CARBOXYLIC ACID AND USES THEREOF FOR TREATING DISEASES AND DISORDERS ASSOCIATED WITH ORNITHINE AMINOTRANSFERASE ACTIVITY | NORTHWESTERN UNIVERSITY (US) | 2020-09-24 | — | — | US | disclosed |
| US-20200281880-A1 | INACTIVATORS OF TOXOPLASMA GONDII ORNITHINE AMINOTRANSFERASE FOR TREATING TOXOPLASMOSIS AND MALARIA | NORTHWESTERN UNIVERSITY (US) | 2020-09-10 | — | — | US | disclosed |
| US-10632088-B2 | Inactivators of Toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria | NORTHWESTERN UNIVERSITY (US) | 2020-04-28 | — | — | US | disclosed |
| US-20180098952-A1 | INACTIVATORS OF TOXOPLASMA GONDII ORNITHINE AMINOTRANSFERASE FOR TREATING TOXOPLASMOSIS AND MALARIA | NORTHWESTERN UNIVERSITY (US) | 2018-04-12 | — | — | US | disclosed |
| US-9603820-B2 | Ornithine aminotransferase inhibition with GABA analogues for treatment of hepatocellular carcinoma | NORTHWESTERN UNIVERSITY (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160128958-A1 | Ornithine Aminotransferase Inhibition with GABA Analogues for Treatment of Hepatocellular Carcinoma | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2016-05-12 | — | — | US | disclosed |
| US-20120245380-A1 | Inhibition of Ornithine Aminotransferase for the Treatment of Proliferative Disorders | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD. (IL) | 2012-09-27 | — | — | US | disclosed |
| US-20120245380-A1 | Inhibition of Ornithine Aminotransferase for the Treatment of Proliferative Disorders | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD. (IL) | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160128958-A1 | Ornithine Aminotransferase Inhibition with GABA Analogues for Treatment of Hepatocellular Carcinoma | OAT, OTC, ODC1 | OAT 1/4885ABAT 6/4885GABRR1 45/4885 |
| US-20200299296-A1 | ANALOGS OF 3-AMINO-4-(PROPAN-2-YLIDENE)CYCLOPENTANE-1-CARBOXYLIC ACID AND USES THEREOF FOR TREATING DISEASES AND DISORDERS ASSOCIATED WITH ORNITHINE AMINOTRANSFERASE ACTIVITY | OAT, OTC, GOT2 | OAT 1/4885ABAT 9/4885GABRR1 1933/4885 |
| US-20180098952-A1 | INACTIVATORS OF TOXOPLASMA GONDII ORNITHINE AMINOTRANSFERASE FOR TREATING TOXOPLASMOSIS AND MALARIA | OAT, OTC, ABAT | OAT 1/4885ABAT 3/4885GABRR1 96/4885 |
| US-11207283-B2 | Inactivators of toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria | OAT, OTC, ABAT | OAT 1/4885ABAT 3/4885GABRR1 96/4885 |
| US-20200281880-A1 | INACTIVATORS OF TOXOPLASMA GONDII ORNITHINE AMINOTRANSFERASE FOR TREATING TOXOPLASMOSIS AND MALARIA | OAT, OTC, ABAT | OAT 1/4885ABAT 3/4885GABRR1 96/4885 |
| US-10632088-B2 | Inactivators of Toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria | OAT, OTC, ABAT | OAT 1/4885ABAT 3/4885GABRR1 96/4885 |
| US-20120245380-A1 | Inhibition of Ornithine Aminotransferase for the Treatment of Proliferative Disorders | OAT, OTC, BCAT1 | OAT 1/4885ABAT 8/4885GABRR1 835/4885 |
| US-11203596-B2 | Analogs of 3-amino-4-(propan-2-ylidene)cyclopentane-1-carboxylic acid and uses thereof for treating diseases and disorders associated with ornithine aminotransferase activity | OAT, OTC, GOT2 | OAT 1/4885ABAT 9/4885GABRR1 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.